Last reviewed · How we verify
Hyaluronic acid 1%
At a glance
| Generic name | Hyaluronic acid 1% |
|---|---|
| Also known as | groupIII |
| Sponsor | Pia Lopez Jornet |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- USC-Exos in Corpus Spongiosum Reconstruction for Hypospadias (NA)
- Clinical Investigation on Lips Treated With HA-filler (NA)
- Hyaluronic Acid and Albumin-PRF in Non-Surgical Periodontal Therapy (NA)
- A Clinical Investigation of the Decoria® Aesthetic Group (DAG) for Correction of Nasolabial Folds (NLF) (NA)
- A Post-market-clinical Follow-up Investigation of Safety and Performance by Decoria® Voluma (NA)
- Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis (PHASE3)
- Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients (NA)
- Efficacy of Therapy With PRP Injections Versus HA in Patients With Advanced Grade of GONArthrosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyaluronic acid 1% CI brief — competitive landscape report
- Hyaluronic acid 1% updates RSS · CI watch RSS
- Pia Lopez Jornet portfolio CI